We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Tanvex Draws Complete Response Letter for Neupogen Biosimilar
Tanvex Draws Complete Response Letter for Neupogen Biosimilar
The FDA issued a complete response letter to Tanvex BioPharma for its proposed biosimilar for Amgen’s Neupogen (filgrastim) for the creation of white blood cells following chemotherapy.